Home

arrow iconNewsarrow iconarrow icon

Minnesota Bill for Infertility Treatments Expands Insurance Coverage by 2027

Minnesota Bill for Infertility Treatments Expands Insurance Coverage by 2027

The Minnesota bill for infertility treatments mandates comprehensive insurance coverage for diagnosis, IVF, and fertility preservation across public and private health plans. Set for implementation in 2027, the legislation expands access, modernises infertility definitions, and ensures cost-sharing protections to make reproductive healthcare more equitable.

By FertilityIn

10 Mar 2026

4 min read

Minnesota Legislature

Minnesota Legislature

Major Takeaways from SF 1961

  • Mandatory Coverage Expansion: All health plans in Minnesota that provide maternity benefits must now include comprehensive coverage for the diagnosis and treatment of infertility, as well as standard fertility preservation services.
  • Public Program Integration: The legislation extends these requirements to Medical Assistance and MinnesotaCare, ensuring that low-income residents have access to the same reproductive technologies as those with private insurance.
  • Modernised Definition of Infertility: The bill defines infertility not only by the traditional failure to conceive after 6 or 12 months but also by a person’s inability to reproduce as a single individual or with a partner without medical intervention.
  • Clinical Standards and Limits: Coverage includes unlimited embryo transfers and up to four completed oocyte retrievals, adhering to professional guidelines from the American Society for Reproductive Medicine.
  • Cost-Sharing Parity: Health plans are prohibited from imposing deductibles, co-payments, or coinsurance for infertility treatments that are higher than those for maternity services.


Minnesota Legislative Shift Promises Comprehensive Fertility Access by 2027

The landscape of reproductive healthcare in the Midwest is poised for a significant transformation following the advancement of SF 1961. This Minnesota bill for infertility treatments seeks to eliminate the financial and diagnostic barriers that have historically hindered family-building for thousands of residents. By mandating that any health plan offering maternity benefits must also cover infertility care, the state is moving toward a model where reproductive medicine is treated as a fundamental component of healthcare.


A primary pillar of the legislation is its commitment to healthcare equity. Under the new requirements, the state’s public health programs Medical Assistance and MinnesotaCare, will be required to cover infertility diagnosis, treatment, and preservation services. This move is designed to ensure that a resident's socioeconomic status does not dictate their ability to access advanced medical interventions like IVF or egg freezing.


The Minnesota bill for infertility treatments also addresses the needs of patients facing "iatrogenic" infertility, requiring coverage for preservation services when a medical treatment, such as chemotherapy, poses a risk to future fertility.


The bill’s inclusive definition of infertility marks a departure from restrictive older statutes. It recognises infertility based on a patient’s medical and reproductive history or their inability to reproduce as a single individual or with a partner, effectively broadening access for the LGBTQ+ community and single parents by choice. Clinically, the mandate requires that treatments align with the professional standards set by the American Society for Reproductive Medicine. While the bill allows insurance providers to cap completed oocyte retrievals at four, it mandates unlimited embryo transfers, prioritising the most effective path to a live birth.


To protect patients from predatory plan designs, the legislation includes strict cost-sharing protections. Health plans are forbidden from applying waiting periods, referral requirements, or benefit maximums to infertility care that do not also apply to standard maternity coverage. This ensures that the Minnesota bill for infertility treatments provides meaningful financial relief rather than just theoretical access.


The implementation of these changes is scheduled for January 1, 2027, for all plans issued or renewed on or after that date. To assist with the transition, the state has established a reimbursement framework where the commissioner of commerce will use general fund appropriations to defray the additional costs incurred by health plan companies. This legislative framework represents a systemic effort to integrate fertility care into the standard continuum of medical services in Minnesota

31 views

Share

FertilityIn

Send Enquiry for this Story

Related Articles

Sapyen Partners with My Surrogacy Journey to Enhance Fertility Testing and Reproductive Health Services Across the U.S.

Sapyen Partners with My Surrogacy Journey to Enhance Fertility Testing and Reproductive Health Services Across the U.S.

apyen, a global leader in male fertility diagnostics, has entered a strategic partnership with My Surrogacy Journey to broaden fertility testing and reproductive health support for intended parents across the United States. The collaboration covers semen analysis, DNA fragmentation testing, and infectious disease screening, with plans for international expansion.

ART

1 min read

Fertility Institute of Hawaii Joins Nucleus IVF+ Network as Genetic Optimization Demand Expands

Fertility Institute of Hawaii Joins Nucleus IVF+ Network as Genetic Optimization Demand Expands

Nucleus Genomics has announced that the Fertility Institute of Hawaii Joins Nucleus IVF+ network, bringing advanced carrier and embryo screening to Hawaii's largest IVF practice. The partnership expands genetic optimization access across the Pacific, with risk reduction data covering endometriosis, heart disease, breast cancer, type 1 diabetes, and Alzheimer's disease.

ART

1 min read

Taiwan Pioneers AI-Powered Embryo Selection Model, Improving Chromosomally Normal Embryo Identification Rate by Up to 24%

Taiwan Pioneers AI-Powered Embryo Selection Model, Improving Chromosomally Normal Embryo Identification Rate by Up to 24%

TFC Taipei Fertility Center has introduced an AI-Powered Embryo Selection model that improves chromosomally normal embryo identification by up to 24%. Presented at ASPIRE 2026, the iDAScore v2.0 system brings precision and objectivity to IVF treatment, reducing implantation failure risk and shortening time to conception for infertile patients.

ART

1 min read

CDT Equity Completes Global Patent Coverage for AZD5904 in Male Infertility Following Canadian Grant

CDT Equity Completes Global Patent Coverage for AZD5904 in Male Infertility Following Canadian Grant

CDT Equity Inc. (Nasdaq: CDT) has announced the Canadian patent grant for AZD5904 in male infertility, completing approval across all key pharmaceutical target markets. The milestone strengthens CDT's IP position for the AstraZeneca-licensed Myeloperoxidase inhibitor as the company advances active out-licensing and strategic partnering discussions for the asset.

ART

1 min read

Nucleus IVF+ Joins SCRC to Bring Genetic Optimization to One of America's Most In-Demand Fertility Centers

Nucleus IVF+ Joins SCRC to Bring Genetic Optimization to One of America's Most In-Demand Fertility Centers

Nucleus Genomics has announced that Nucleus IVF+ joins SCRC, the Southern California Reproductive Center, as part of its rapidly expanding global network. The partnership integrates advanced carrier screening and embryo analysis across SCRC's four California locations, serving thousands of patients annually across Beverly Hills, Santa Barbara, Pasadena, and Ventura.

ART

1 min read

UNC Fertility Sets Strategic Collaboration with IVI RMA North America to enhance Patient Care and Clinical Excellence

UNC Fertility Sets Strategic Collaboration with IVI RMA North America to enhance Patient Care and Clinical Excellence

UNC Fertility has announced its plans for Collaboration with IVI RMA North America to bring best clinical and operational best practices across the region, expanding access to cutting-edge fertility treatments and research.

ART

1 min read

AI-Powered Embryo Assessment Gets FDA Green Light as Alife Health Clears Regulatory Milestone

AI-Powered Embryo Assessment Gets FDA Green Light as Alife Health Clears Regulatory Milestone

Alife Health has secured FDA clearance for Embryo Predict, its AI-powered embryo assessment tool for IVF. Backed by a 440-patient, seven-center randomized clinical trial, the platform delivers data-driven embryo selection insights to embryologists across the U.S., Europe, and the U.K., addressing longstanding variability in clinical decision-making.

ART

1 min read

Landing Page Image

Subscribe to our Newsletter

Stay updated with the latest news, expert insights, and exclusive offers delivered straight to your inbox. Join our community today!

Email Address